×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 1506: REGULATORY, SCIENTIFIC, AND CONSIDERATIONS OF BIOSIMILAR DEVELOPMENT (PART II)
Session Chair(s)
Ning Li, MD, PhD
Vice President, Head of Asia Regulatory and Medical Policy
Sanofi, China
Session 1506: REGULATORY, SCIENTIFIC, AND CONSIDERATIONS OF BIOSIMILAR DEVELOPMENT (PART II)
Speaker(s)
The Biosimilars Challenge in the US
ChihLu Yu
Schiff Hardin LLP, USA, China
Counsel
Quality and Regulatory Considerations for Biosimilar Product Development in China
Lichung Huang
Henlius Biopharmaceuticals, Inc., China
Biosimilar - Legal and Regulatory Issues
Shaoyu Chen, JD
Covington & Burling LLP, China
Managing Director, China Food and Drug Practice; Partner
Have an account?